Welcome to our dedicated page for First Wave BioPharma news (Ticker: FWBI), a resource for investors and traders seeking the latest updates and insights on First Wave BioPharma stock.
First Wave BioPharma, Inc. reports clinical-stage biopharmaceutical developments focused on targeted, non-systemic therapies for gastrointestinal diseases. Recurring news includes updates on latiglutenase, an oral biotherapeutic composed of gluten-specific recombinant proteases for celiac disease, as well as scientific publications, conference abstracts, and diagnostic research related to serologic and mucosal measures in celiac disease.
Company updates also cover investor conference participation, clinical development strategy, material agreements, shareholder voting matters, capital-structure disclosures, governance items, operating results, and clinical or regulatory disclosures tied to its GI disease pipeline.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
On April 25, 2023, First Wave BioPharma announced significant progress in its Phase 2 SPAN clinical trial for adrulipase, a treatment aimed at exocrine pancreatic insufficiency (EPI) in cystic fibrosis patients. The company has surpassed the 50% enrollment target with three U.S. trial sites actively screening patients. The study is a dose-escalation trial involving 12 patients, focusing on safety, tolerability, and efficacy, with topline results expected in July 2023. Adrulipase is a recombinant lipase enzyme designed to aid fat digestion and reduce malabsorption symptoms. Approximately 40,000 U.S. patients suffer from EPI due to cystic fibrosis.
First Wave BioPharma (NASDAQ: FWBI) announced a private placement agreement to issue 1,023,018 shares of common stock at $3.91 each, raising approximately $4.0 million before fees. The agreement includes warrants for an additional 2,046,036 shares at an exercise price of $3.66, valid for five years. The private placement is expected to close around March 15, 2023, subject to customary conditions. Proceeds will be used for working capital. The company plans to file a registration statement for resale of the shares with the SEC shortly. This offering adheres to SEC regulations, limiting sales to registered entities.